Questions: Method Development Lifecycle

Question 1

A pharmaceutical company develops and validates an HPLC method in its R&D lab, then sends it to a manufacturing site in another country. The receiving lab's results fall 8% outside the acceptance range. Which lifecycle stage was skipped or inadequately performed?

• A. Method validation — validation is not complete until multiple laboratories confirm the results
• B. Method transfer — a formal transfer protocol should have demonstrated equivalent performance at the receiving site before routine use
• C. Analytical target profile definition — the ATP was not shared with the receiving laboratory
• D. Revalidation — the method requires full revalidation whenever it moves to a new site

Answer: (B)

Method transfer is the formal process of demonstrating that a receiving laboratory can achieve performance equivalent to the originating site. Both sites analyze the same sample set and apply statistical equivalence tests. Skipping this step is a common cause of performance failures when methods are transferred — which is why transfer is a distinct lifecycle stage with its own protocol, not merely 'sending the method document.' Revalidation (option D) would be required if a significant change to the method occurred, not just a site change.

Question 2

A chemist optimizes an HPLC separation by first fixing all other variables and varying pH until pH 3.5 gives the best result. She then fixes pH at 3.5 and varies organic solvent percentage, finding 30% optimal. What is the primary weakness of this approach?

• A. No weakness — one-factor-at-a-time optimization is the most rigorous approach because each factor is tested in isolation
• B. OFAT misses interactions between factors: the optimal pH at 30% solvent may differ from the optimal pH tested at the original solvent level, so the true optimum may never be found
• C. The approach is valid but slow; DOE reaches the same optimum with fewer experiments
• D. OFAT is only valid for pH optimization; solvent percentage requires a different approach

Answer: (B)

This is one-factor-at-a-time (OFAT) optimization, a known limitation in method development. If pH and organic solvent percentage interact — meaning the best pH changes depending on solvent level — OFAT will find a local rather than global optimum. Design of experiments (DOE) varies multiple factors simultaneously according to a statistical design, builds a response surface model, and reveals exactly these interactions. Interactions are common in chromatographic separations, which is why DOE is now standard practice.

Question 3

A validated analytical method may require revalidation after switching to a column from a new supplier, even if the new column is described as 'equivalent' to the original.

• T. True
• F. False

Answer: True

Even nominally equivalent substitutions — a 'same chemistry' column from a different manufacturer — can affect selectivity, retention, and resolution in ways that are not predictable from specifications alone. Quality systems and regulatory frameworks (ICH Q2, USP <1226>) require assessing whether any change affects method performance. If the change is significant enough to affect critical parameters (resolution, peak shape, retention time), partial or full revalidation is required. 'Equivalent by specification' does not guarantee 'equivalent in performance.'

Question 4

Once a method passes formal validation, it is fit for purpose indefinitely and requires no further monitoring or revalidation.

• T. True
• F. False

Answer: False

Method validation demonstrates fitness for purpose at the time and conditions of validation. Methods degrade over time as reagent lots change, instruments age, sample matrices evolve, and regulatory expectations tighten. Quality systems require ongoing monitoring — system suitability tests, control charts, periodic proficiency testing — to ensure methods remain in control. Significant changes (new column supplier, instrument upgrade, new sample type) can trigger partial or full revalidation. 'Validated once, valid forever' is a misconception the lifecycle framework explicitly rejects.

Question 5

What is an analytical target profile (ATP) and why must it be defined before method development begins rather than after?

Model answer: The analytical target profile is a clear specification of what the method must accomplish: what analyte, in what matrix, at what concentration range, with what precision, accuracy, specificity, and other performance requirements. It functions as the method's requirements document. Without it, development becomes aimless optimization with no agreed criterion for success — you could optimize indefinitely without knowing when you're done. With it, every experimental decision has a clear evaluation standard: does this condition bring me closer to meeting the ATP? The ATP also defines when validation is complete and when revalidation is required.

The ATP concept represents a shift from 'develop a method and then see what it can do' to 'define what you need, then develop to meet it.' This matters practically because retrospectively discovering that a method doesn't meet an unstated requirement (e.g., the matrix suppresses signal more than tolerable) requires starting over. Defining the ATP first ensures that the development effort is directed toward a measurable target.